Suppr超能文献

接种 SARS-CoV-2 疫苗后发生格雷夫斯病:已报告病例的系统回顾。

Graves' disease following vaccination against SARS-CoV-2: A systematic review of the reported cases.

机构信息

Society of Meta-research and Biomedical Innovation, London, United Kingdom.

Department of Nutrition and Dietetics, Homerton University Hospital Foundation Trust, London, United Kingdom.

出版信息

Front Endocrinol (Lausanne). 2022 Sep 27;13:938001. doi: 10.3389/fendo.2022.938001. eCollection 2022.

Abstract

The newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, thyroid dysfunction, including Graves' disease, has been observed after administration of different COVID-19 vaccines, although causality remains a matter of debate. The aim of this systematic review was to examine the available literature and provide an overview of reported cases of Graves' disease following COVID-19 vaccination. We identified 21 eligible articles which included 57 patients with Graves' disease following COVID-19 vaccination. Fourteen participants were males (25%, 14/57) and 43 (75%, 44/57) were females with a mean age of 44.3 years. The most common presenting symptom was palpitations (63%, 27/43) followed by weight loss (35%, 15/43). The majority of patients received thionamides (47%, 25/53). The clinical status after treatment was provided for 37 patients and it was improved in the majority of them (84%, 31/37). Graves' disease is possibly a condition clinicians may expect to encounter in patients receiving COVID-19 vaccines. While the above adverse event is rare, considering the scarcity of available data in scientific literature, and causality is not yet confirmed, the increased awareness of clinicians and the early recognition of the disorder are important for the optimal management of these patients.

摘要

新开发的 COVID-19 疫苗已经建立了安全的概况,但一些人会经历各种不良反应。最近,在使用不同的 COVID-19 疫苗后,观察到甲状腺功能障碍,包括格雷夫斯病,尽管因果关系仍存在争议。本系统评价的目的是检查现有文献,并概述 COVID-19 疫苗接种后报告的格雷夫斯病病例。我们确定了 21 篇符合条件的文章,其中包括 57 例 COVID-19 疫苗接种后发生格雷夫斯病的患者。14 名参与者为男性(25%,14/57),43 名(75%,44/57)为女性,平均年龄为 44.3 岁。最常见的首发症状是心悸(63%,27/43),其次是体重减轻(35%,15/43)。大多数患者接受了硫脲类药物(47%,25/53)治疗。37 例患者提供了治疗后的临床状况,其中大多数(84%,31/37)得到改善。格雷夫斯病可能是临床医生在接受 COVID-19 疫苗接种的患者中可能遇到的情况。虽然上述不良事件较为罕见,但鉴于科学文献中可用数据的稀缺性,且因果关系尚未得到证实,提高临床医生的认识和早期识别该疾病对于这些患者的最佳管理非常重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验